Key result
Compound 3l, a novel P2Y1 antagonist, demonstrated a robust oral antithrombotic effect with mild bleeding liability in rat thrombosis and hemostasis models.
Why the study?
Does the novel P2Y1 antagonist compound 3l provide oral antithrombotic efficacy with reduced bleeding liability in rat models?
Population
Preclinical rat models for thrombosis and hemostasis
Design
Preclinical
Authors
Loading...
Supports progression to human studies for oral antithrombotic therapy; leaves open efficacy and safety in patients.
Does the novel P2Y1 antagonist compound 3l provide oral antithrombotic efficacy with reduced bleeding liability in rat models?
Compound 3l is a novel, orally bioavailable P2Y1 antagonist that shows robust antithrombotic efficacy with mild bleeding liability in preclinical rat models.
Qiao et al. (2013) studied Thrombosis. Compound 3l (P2Y1 antagonist) was evaluated on Antithrombotic effect and bleeding liability in rat models. Compound 3l, a novel P2Y1 antagonist, demonstrated a robust oral antithrombotic effect with mild bleeding liability in rat thrombosis and hemostasis models.